We are live on ! Find out more
TRAW icon

Traws Pharma
TRAW

17 hedge funds and large institutions have $38.2M invested in Traws Pharma in 2013 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

23% less funds holding

Funds holding: 22 → 17 (-5)

50% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 10

62% less capital invested

Capital invested by funds: $102M → $38.2M (-$63.3M)

Holders
17
Holders Change
-5
Holders Change %
-22.73%
% of All Funds
0.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
5
Reduced
1
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$10.4M
2
BFA
BlackRock Fund Advisors
California
+$3.79M
3
WMSA
Weiss Multi-Strategy Advisers
New York
+$2.84M
4
EA
Emerald Advisers
Pennsylvania
+$1.89M
5
Ameriprise
Ameriprise
Minnesota
+$947K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$25.6M
2
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$5.19M
3
WC
Weatherbie Capital
Massachusetts
-$4.73M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.85M
5
JP Morgan Chase
JP Morgan Chase
New York
-$3.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$10.7M +$10.4M +11 +183%
BFA
2
BlackRock Fund Advisors
California
$4.71M +$3.79M +4 +133%
EA
3
Emerald Advisers
Pennsylvania
$4.22M +$1.89M +2 +40%
Wells Fargo
4
Wells Fargo
California
$3.34M +$947K +1 +25%
WMSA
5
Weiss Multi-Strategy Advisers
New York
$2.35M +$2.84M +3 +300%
WC
6
Weatherbie Capital
Massachusetts
$2.03M -$4.73M -5 -63%
SFM
7
Sphera Funds Management
Israel
$1.38M +$1.89M +2 New
Northern Trust
8
Northern Trust
Illinois
$937K – – –
Arrowstreet Capital
9
Arrowstreet Capital
Massachusetts
$935K +$947K +1 New
Vanguard Group
10
Vanguard Group
Pennsylvania
$920K – – –
State Street
11
State Street
Massachusetts
$708K – – –
BIT
12
BlackRock Institutional Trust
California
$616K – – –
Deutsche Bank
13
Deutsche Bank
Germany
$569K – – –
ARTA
14
A.R.T. Advisors
New York
$490K +$947K +1 New
Ameriprise
15
Ameriprise
Minnesota
$383K +$947K +1 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$348K – – –
CCA
17
Catalyst Capital Advisors
New York
$287K – – –
EAM
18
Eventide Asset Management
Massachusetts
$264K – – –
TCIM
19
TIAA CREF Investment Management
New York
$263K – – –
SIM
20
SSI Investment Management
California
$247K – – –
TAM
21
Tocqueville Asset Management
New York
$232K – – –
SB
22
Suntrust Banks
Georgia
$192K – – –
Bank of New York Mellon
23
Bank of New York Mellon
New York
$187K – – –
BIM
24
BlackRock Investment Management
Delaware
$186K – – –
Morgan Stanley
25
Morgan Stanley
New York
$184K -$947K -1 Closed
1
2 3

TRAW Hedge Fund Activity: Q4 2013 in Review

17 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q4 2013, worth a combined $38.2M — down 62% from $102M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of TRAW and 5 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 5 added.

The largest buyer was Fidelity Investments, adding an estimated $10.4M. The largest seller was Deerfield Management, exiting entirely with an estimated $25.6M sold.

  • 17 institutional investors held Traws Pharma (TRAW) as of Q4 2013, down from 22 in Q3 2013.
  • Funds reported $38.2M of Traws Pharma stock for Q4 2013, down 62% quarter-over-quarter.
  • 5 funds opened new Traws Pharma positions in Q4 2013 and 10 closed out, a net change of -5 holders.
  • The largest Traws Pharma buyer in Q4 2013 was Fidelity Investments, an estimated $10.4M added.
  • The largest Traws Pharma seller in Q4 2013 was Deerfield Management, an estimated $25.6M sold.

Based on aggregated 13F filings for Q4 2013.